Drug intelligence / Profile preview

BWH-03

Development stage: Preclinical
Lead developer: Shanghai Argo Biopharmaceutical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

BWH-03 is a preclinical-stage small interfering RNA (siRNA) therapeutic developed by Argo Biopharma (Chengdu Xinzhenghe Pharmaceutical Technology) for the treatment of heart disease. The drug utilizes RNA interference (RNAi) technology to silence the expression of a specific gene involved in cardiovascular pathology. As of 2024, BWH-03 remains in the preclinical phase of development, forming part of Argo Biopharma's broader pipeline of RNA-based therapies targeting metabolic and cardiovascular conditions.

Other names: BWH-03BWH03BWH 03

Beyond the preview

Go deeper on BWH-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BWH-03.

Explore the full profile